Dr. Shen Xiangyang, Microsoft's global executive vice president, head of Microsoft's artificial intelligence and Microsoft research division, announced to Airco, Microsoft China and Lilly China that many of the artificial intelligence companies in the company have already cooperated and will jointly promote medical technology with artificial intelligence technology. The health industry is transforming into digital.
Recently, Lilly China and Microsoft China reached a strategic cooperation, and Lilly China will use the artificial intelligence screening solution developed by Microsoft partner Airdoc.
Julio Gay-Ger, President and General Manager of Lilly China, said: “As an international pharmaceutical company with more than 140 years of history, Eli Lilly is committed to meeting the needs of patients and markets by providing innovative medicines and support services. People's life is better. This year is the 100th anniversary of Lilly's entry into China. With the philosophy of 'rooting China, benefiting China' and its commitment to Chinese patients and society, Lilly will continue to strengthen innovation and external cooperation to bring patients High-quality, personalized treatment solutions and support services. At present, artificial intelligence has risen to the national strategy, and health care is one of the most potential areas of artificial intelligence applications. Lilly is willing to actively promote artificial intelligence, cloud computing, etc. in medical Innovative applications in the field of health, through strategic cooperation with Microsoft, explore the use of technological innovation to empower medical care, and help the implementation of the 'Health China 2030' planning outline, ultimately benefiting the majority of patients."
Alain Crozier, senior vice president of Microsoft and chairman and CEO of Greater China, said: "From the world to China, Microsoft is very pleased to work with leading companies in various industries to actively explore different technologies. The digital transformation of the industry. Lilly is a company that actively embraces innovation and is committed to building a better future for humanity. Microsoft is very honored to have a strategic cooperation with Lilly. Through strategic cooperation with Lilly, we will work together with our partners. Discover the strengths and potential of Microsoft's artificial intelligence, Azure cloud services, Office 365 and other products and services to create a new benchmark for digital transformation in the healthcare industry."
What role will AI play in medical treatment?
Airdoc is one of the world's leading manufacturers of artificial intelligence in the field of medical and health care. It is one of the first companies in the world to start clinical application of deep learning-based auxiliary diagnostic system. In the pioneering work in the medical artificial intelligence industry, Airdoc chronic disease recognition algorithm can be based on retinal image recognition. Chronic diseases and complications such as diabetes, hypertension, arteriosclerosis, optic nerve disease, high myopia, age-related macular degeneration, etc.
Compared with image recognition in other fields, medical image pixels are larger, so there is a high demand for computing power. Many practitioners need to solve the problem of large-scale computing, and CNTK can achieve higher performance in distributed training. Acceleration ratio, and with the support of Microsoft Azure, can significantly improve the accuracy and efficiency of major disease screening, so Airdoc and Microsoft have maintained in-depth cooperation.
In order to achieve early detection and early treatment of diseases, help patients improve their quality of life and reduce treatment costs, Lilly China plans to use the artificial intelligence screening solution developed by Microsoft partner Airdoc to automatically analyze the patient's medical imaging data to achieve disease. Early detection. Based on the Microsoft Cognitive Toolkit Deep Learning Framework, this program runs on Microsoft Smart Cloud Azure and significantly improves the accuracy and efficiency of critical disease screening.
With Lilly's leading market position in the healthcare industry and forward-looking exploration in the digital arena, combined with Microsoft's cutting-edge artificial intelligence, cloud computing services and ecosystem, Airdoc's technology and market resources in the field of chronic diseases promote technology together. Innovation to improve patient life, promote communication between doctors and patients, empower employees, and optimize business processes.
On April 28, 2018, the General Office of the State Council issued the "Opinions on Promoting the Development of "Internet + Medical Health"", officially blew the horn of "Smart Medicine, Healthy China", and promoted and supported the development of "Internet + Medical Health". It is mainly based on artificial intelligence technology and mobile medical demonstration of medical health intelligent devices, so as to realize real-time monitoring and evaluation of personal health, disease early warning, chronic disease screening, and active intervention.
The new service model and new format of “Internet + Medical Health†have provided opportunities and challenges for the transformation of the entire medical industry , and also set the platform and trend for the digital transformation of medical care.
Artificial intelligence will extend the capabilities of human beings. This requires that artificial intelligence must be designed and developed on a human-based basis, with people first—people-centred. In the future, Microsoft China, Lilly China, and Airdoc will empower medical care through artificial intelligence.
Diagnostic reagents can be divided into two categories: in vivo diagnostic reagents and in vitro diagnostic reagents. It is mostly a reagent for detection by the reaction between antigen and antibody.
A: Classification of in vitro diagnostic reagents:
1. In vitro biodiagnostic reagents managed as drugs include:
1. Blood type and tissue type reagents;
2. Microbial antigen, antibody and nucleic acid detection reagents;
3. Tumor marker reagents;
4. Immunohistochemistry and human tissue cell reagents;
5. Human genetic testing reagents;
6. Biochips;
7. Allergy diagnostic reagents.
2. In vitro reagents managed as medical devices include:
1. Clinical basic test reagents;
2. Clinical chemistry reagents;
3. Blood gas and electrolyte determination reagents;
4. Vitamin determination reagents;
5. Cell histochemical stains;
6. Autoimmune diagnostic reagents;
7. Microbiological test reagents.
B: According to medical test items, clinical diagnostic reagents can be roughly divided into clinical chemical test reagents, immunology and
Serological testing reagents, hematological and cytogenetic testing reagents, microbiological testing reagents, body fluid excretion
Detection reagents, genetic diagnosis reagents, etc. Among them, the market share of clinical chemistry
The largest, close to 34%; followed by the immunology market, accounting for about 29%. Novel immunodiagnostic reagents and genetic diagnostic tests
The reagent was developed in the late 1980s, and it is the most common diagnostic reagent for all current diagnostic reagents, regardless of technology or market.
The fastest growing product.
Urine Rapid Test Kit,Rapid Test Kit 6-Panel,Toxoplasma rapid test kits,Fecal Occult Blood Test
Jilin Sinoscience Technology Co. LTD , https://www.jlgkscience.com